A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus

Bronwyn M. Gunn, Wen Han Yu, Marcus M. Karim, Jennifer M. Brannan, Andrew S. Herbert, Anna Z. Wec, Peter J. Halfmann, Marnie L. Fusco, Sharon L. Schendel, Karthik Gangavarapu, Tyler Krause, Xiangguo Qiu, Shinhua He, Jishnu Das, Todd J. Suscovich, Jonathan R. Lai, Kartik Chandran, Larry Zeitlin, James E. Crowe, Douglas Lauffenburger & 6 others Yoshihiro Kawaoka, Gary P. Kobinger, Kristian G. Andersen, John M. Dye, Erica Ollmann Saphire, Galit Alter

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The recent Ebola virus (EBOV) epidemic highlighted the need for effective vaccines and therapeutics to limit and prevent outbreaks. Host antibodies against EBOV are critical for controlling disease, and recombinant monoclonal antibodies (mAbs) can protect from infection. However, antibodies mediate an array of antiviral functions including neutralization as well as engagement of Fc-domain receptors on immune cells, resulting in phagocytosis or NK cell-mediated killing of infected cells. Thus, to understand the antibody features mediating EBOV protection, we examined specific Fc features associated with protection using a library of EBOV-specific mAbs. Neutralization was strongly associated with therapeutic protection against EBOV. However, several neutralizing mAbs failed to protect, while several non-neutralizing or weakly neutralizing mAbs could protect. Antibody-mediated effector functions, including phagocytosis and NK cell activation, were associated with protection, particularly for antibodies with moderate neutralizing activity. This framework identifies functional correlates that can inform therapeutic and vaccine design strategies against EBOV and other pathogens. While antibodies provide protection against Ebola virus, the mechanism is unclear. Gunn et al. dissect the contribution of Fc-functions to protection using a library of Ebola virus-specific antibodies. Fc function was a critical predictor of protection across neutralizing and non-neutralizing antibodies, pointing to synergy between Fc- and Fab-mediated antibody-functions against Ebola.

Original languageEnglish (US)
Pages (from-to)221-233.e5
JournalCell Host and Microbe
Volume24
Issue number2
DOIs
StatePublished - Aug 8 2018

Fingerprint

Ebolavirus
Monoclonal Antibodies
Antibodies
Therapeutics
Neutralizing Antibodies
Phagocytosis
Natural Killer Cells
Vaccines
Fc Receptors
Antiviral Agents
Disease Outbreaks

Keywords

  • antibodies
  • Ebola virus
  • effector function
  • Fc-receptors
  • immunotherapeutics
  • innate immunity
  • phagocytosis

ASJC Scopus subject areas

  • Parasitology
  • Microbiology
  • Virology

Cite this

Gunn, B. M., Yu, W. H., Karim, M. M., Brannan, J. M., Herbert, A. S., Wec, A. Z., ... Alter, G. (2018). A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. Cell Host and Microbe, 24(2), 221-233.e5. https://doi.org/10.1016/j.chom.2018.07.009

A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. / Gunn, Bronwyn M.; Yu, Wen Han; Karim, Marcus M.; Brannan, Jennifer M.; Herbert, Andrew S.; Wec, Anna Z.; Halfmann, Peter J.; Fusco, Marnie L.; Schendel, Sharon L.; Gangavarapu, Karthik; Krause, Tyler; Qiu, Xiangguo; He, Shinhua; Das, Jishnu; Suscovich, Todd J.; Lai, Jonathan R.; Chandran, Kartik; Zeitlin, Larry; Crowe, James E.; Lauffenburger, Douglas; Kawaoka, Yoshihiro; Kobinger, Gary P.; Andersen, Kristian G.; Dye, John M.; Saphire, Erica Ollmann; Alter, Galit.

In: Cell Host and Microbe, Vol. 24, No. 2, 08.08.2018, p. 221-233.e5.

Research output: Contribution to journalArticle

Gunn, BM, Yu, WH, Karim, MM, Brannan, JM, Herbert, AS, Wec, AZ, Halfmann, PJ, Fusco, ML, Schendel, SL, Gangavarapu, K, Krause, T, Qiu, X, He, S, Das, J, Suscovich, TJ, Lai, JR, Chandran, K, Zeitlin, L, Crowe, JE, Lauffenburger, D, Kawaoka, Y, Kobinger, GP, Andersen, KG, Dye, JM, Saphire, EO & Alter, G 2018, 'A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus', Cell Host and Microbe, vol. 24, no. 2, pp. 221-233.e5. https://doi.org/10.1016/j.chom.2018.07.009
Gunn, Bronwyn M. ; Yu, Wen Han ; Karim, Marcus M. ; Brannan, Jennifer M. ; Herbert, Andrew S. ; Wec, Anna Z. ; Halfmann, Peter J. ; Fusco, Marnie L. ; Schendel, Sharon L. ; Gangavarapu, Karthik ; Krause, Tyler ; Qiu, Xiangguo ; He, Shinhua ; Das, Jishnu ; Suscovich, Todd J. ; Lai, Jonathan R. ; Chandran, Kartik ; Zeitlin, Larry ; Crowe, James E. ; Lauffenburger, Douglas ; Kawaoka, Yoshihiro ; Kobinger, Gary P. ; Andersen, Kristian G. ; Dye, John M. ; Saphire, Erica Ollmann ; Alter, Galit. / A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. In: Cell Host and Microbe. 2018 ; Vol. 24, No. 2. pp. 221-233.e5.
@article{c1dfcb05db204b3697fea572ecef8242,
title = "A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus",
abstract = "The recent Ebola virus (EBOV) epidemic highlighted the need for effective vaccines and therapeutics to limit and prevent outbreaks. Host antibodies against EBOV are critical for controlling disease, and recombinant monoclonal antibodies (mAbs) can protect from infection. However, antibodies mediate an array of antiviral functions including neutralization as well as engagement of Fc-domain receptors on immune cells, resulting in phagocytosis or NK cell-mediated killing of infected cells. Thus, to understand the antibody features mediating EBOV protection, we examined specific Fc features associated with protection using a library of EBOV-specific mAbs. Neutralization was strongly associated with therapeutic protection against EBOV. However, several neutralizing mAbs failed to protect, while several non-neutralizing or weakly neutralizing mAbs could protect. Antibody-mediated effector functions, including phagocytosis and NK cell activation, were associated with protection, particularly for antibodies with moderate neutralizing activity. This framework identifies functional correlates that can inform therapeutic and vaccine design strategies against EBOV and other pathogens. While antibodies provide protection against Ebola virus, the mechanism is unclear. Gunn et al. dissect the contribution of Fc-functions to protection using a library of Ebola virus-specific antibodies. Fc function was a critical predictor of protection across neutralizing and non-neutralizing antibodies, pointing to synergy between Fc- and Fab-mediated antibody-functions against Ebola.",
keywords = "antibodies, Ebola virus, effector function, Fc-receptors, immunotherapeutics, innate immunity, phagocytosis",
author = "Gunn, {Bronwyn M.} and Yu, {Wen Han} and Karim, {Marcus M.} and Brannan, {Jennifer M.} and Herbert, {Andrew S.} and Wec, {Anna Z.} and Halfmann, {Peter J.} and Fusco, {Marnie L.} and Schendel, {Sharon L.} and Karthik Gangavarapu and Tyler Krause and Xiangguo Qiu and Shinhua He and Jishnu Das and Suscovich, {Todd J.} and Lai, {Jonathan R.} and Kartik Chandran and Larry Zeitlin and Crowe, {James E.} and Douglas Lauffenburger and Yoshihiro Kawaoka and Kobinger, {Gary P.} and Andersen, {Kristian G.} and Dye, {John M.} and Saphire, {Erica Ollmann} and Galit Alter",
year = "2018",
month = "8",
day = "8",
doi = "10.1016/j.chom.2018.07.009",
language = "English (US)",
volume = "24",
pages = "221--233.e5",
journal = "Cell Host and Microbe",
issn = "1931-3128",
publisher = "Cell Press",
number = "2",

}

TY - JOUR

T1 - A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus

AU - Gunn, Bronwyn M.

AU - Yu, Wen Han

AU - Karim, Marcus M.

AU - Brannan, Jennifer M.

AU - Herbert, Andrew S.

AU - Wec, Anna Z.

AU - Halfmann, Peter J.

AU - Fusco, Marnie L.

AU - Schendel, Sharon L.

AU - Gangavarapu, Karthik

AU - Krause, Tyler

AU - Qiu, Xiangguo

AU - He, Shinhua

AU - Das, Jishnu

AU - Suscovich, Todd J.

AU - Lai, Jonathan R.

AU - Chandran, Kartik

AU - Zeitlin, Larry

AU - Crowe, James E.

AU - Lauffenburger, Douglas

AU - Kawaoka, Yoshihiro

AU - Kobinger, Gary P.

AU - Andersen, Kristian G.

AU - Dye, John M.

AU - Saphire, Erica Ollmann

AU - Alter, Galit

PY - 2018/8/8

Y1 - 2018/8/8

N2 - The recent Ebola virus (EBOV) epidemic highlighted the need for effective vaccines and therapeutics to limit and prevent outbreaks. Host antibodies against EBOV are critical for controlling disease, and recombinant monoclonal antibodies (mAbs) can protect from infection. However, antibodies mediate an array of antiviral functions including neutralization as well as engagement of Fc-domain receptors on immune cells, resulting in phagocytosis or NK cell-mediated killing of infected cells. Thus, to understand the antibody features mediating EBOV protection, we examined specific Fc features associated with protection using a library of EBOV-specific mAbs. Neutralization was strongly associated with therapeutic protection against EBOV. However, several neutralizing mAbs failed to protect, while several non-neutralizing or weakly neutralizing mAbs could protect. Antibody-mediated effector functions, including phagocytosis and NK cell activation, were associated with protection, particularly for antibodies with moderate neutralizing activity. This framework identifies functional correlates that can inform therapeutic and vaccine design strategies against EBOV and other pathogens. While antibodies provide protection against Ebola virus, the mechanism is unclear. Gunn et al. dissect the contribution of Fc-functions to protection using a library of Ebola virus-specific antibodies. Fc function was a critical predictor of protection across neutralizing and non-neutralizing antibodies, pointing to synergy between Fc- and Fab-mediated antibody-functions against Ebola.

AB - The recent Ebola virus (EBOV) epidemic highlighted the need for effective vaccines and therapeutics to limit and prevent outbreaks. Host antibodies against EBOV are critical for controlling disease, and recombinant monoclonal antibodies (mAbs) can protect from infection. However, antibodies mediate an array of antiviral functions including neutralization as well as engagement of Fc-domain receptors on immune cells, resulting in phagocytosis or NK cell-mediated killing of infected cells. Thus, to understand the antibody features mediating EBOV protection, we examined specific Fc features associated with protection using a library of EBOV-specific mAbs. Neutralization was strongly associated with therapeutic protection against EBOV. However, several neutralizing mAbs failed to protect, while several non-neutralizing or weakly neutralizing mAbs could protect. Antibody-mediated effector functions, including phagocytosis and NK cell activation, were associated with protection, particularly for antibodies with moderate neutralizing activity. This framework identifies functional correlates that can inform therapeutic and vaccine design strategies against EBOV and other pathogens. While antibodies provide protection against Ebola virus, the mechanism is unclear. Gunn et al. dissect the contribution of Fc-functions to protection using a library of Ebola virus-specific antibodies. Fc function was a critical predictor of protection across neutralizing and non-neutralizing antibodies, pointing to synergy between Fc- and Fab-mediated antibody-functions against Ebola.

KW - antibodies

KW - Ebola virus

KW - effector function

KW - Fc-receptors

KW - immunotherapeutics

KW - innate immunity

KW - phagocytosis

UR - http://www.scopus.com/inward/record.url?scp=85050732898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050732898&partnerID=8YFLogxK

U2 - 10.1016/j.chom.2018.07.009

DO - 10.1016/j.chom.2018.07.009

M3 - Article

VL - 24

SP - 221-233.e5

JO - Cell Host and Microbe

JF - Cell Host and Microbe

SN - 1931-3128

IS - 2

ER -